Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
abazistobart
- Development stage
- Unknown
- Lead developer
- 3S Guojian Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
Abazistobart (609A, SSGJ-609A) is a recombinant humanized immunoglobulin G4 (IgG4) kappa monoclonal antibody targeting programmed cell death protein 1 (PD-1). Developed by Sunshine Guojian, abazistobart acts as an immune checkpoint inhibitor by blocking the interaction between PD-1 and its ligands (PD-L1 and PD-L2), thereby restoring T-cell activation and enhancing anti-tumor immune responses. It is under clinical evaluation for the treatment of various solid tumors, including advanced or unresectable undifferentiated pleomorphic sarcoma (UPS) and other soft tissue sarcomas. Additionally, Sunshine Guojian has partnered with Syncromune to develop abazistobart as part of the SYNC-T (SV-102) multi-mechanistic in situ combination immunotherapy.
- Other names
- Recombinant anti-PD-1 humanized monoclonal antibody injectionmAb1-25-HumanizedmAb-1-25-HumanizedmAb 1-25-Humanized
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)PDCD1LG2 (Programmed cell death 1 ligand 2)
Beyond the preview
Go deeper on abazistobart.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on abazistobart.